(Q43283673)

English

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

scientific article published on 28 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

phase II clinical trial

0 references

acute coronary syndrome

1 reference

based on heuristic

inferred from title

Eugene Braunwald

10

object named as

Eugene Braunwald

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Elliott M Antman

2

object named as

Elliott M Antman

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

3

object named as

Petr Widimsky

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Carolyn F McCabe

9

object named as

Carolyn H McCabe

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Marc S Sabatine

1

object named as

Marc S Sabatine

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Charles F Contant

8

object named as

Charles F Contant

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

author name string

Iftikhar O Ebrahim

4

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Robert G Kiss

5

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

André Saaiman

6

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Rostislav Polasek

7

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

language of work or name

0 references

publication date

28 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

9692

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

787-795

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Mechanisms of thrombus formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bivalirudin for patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Early versus delayed, provisional eptifibatide in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961454-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)61454-9

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43283673&oldid=1985562903"